跳至主要内容
临床试验/EUCTR2013-004191-35-BE
EUCTR2013-004191-35-BE进行中(未招募)1 期

Evaluation of the effects and plasma concentration of the potent platelet inhibitor ticagrelor, after crushed and non-crushed intake, after semi-urgent coronary bypass and in patients after cardiac arrest. - Ticagrelor-study

Ghent University Hospital0 个研究点目标入组 100 人开始时间: 2014年10月30日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Subject with an acute myocardial infarction with ST elevation
  • Subject with an acute myocardial infarction without ST elevation
  • Subject with unstable angina (progressive angina during past 2 weeks, negative cardiac markers, Trop T < 0,014µg/l
  • First time of taking Brilique
  • = 18 years
  • Possibility to take a blood sample before administration of Brilique
  • Signed Informed Consent, signed by subject or authorized representative, able and willing to provide written informed consent for study participation
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 60

排除标准

  • Active haemorrhage
  • Moderate or severe liver failure with coagulopathy
  • Pregnancy and lactation
  • A history of an intra cerebral haemorrhage
  • Patient is HIV positive and treated with Ritonavir and /or Atazanavir
  • Patient treated with vitamin K antagonist or with a new oral anti coagulant
  • Hypersensitivity to ticagrelor or any of the exipients

研究者

相似试验